Infectious Disease Molecular Diagnostics Markets by Syndrome, Plex, Facility and Country with Forecasting/Analysis, Executive Guides and Customization 2022 to 2026
“COVID-19 has changed everything in diagnostics. How big are the changes? What will be the impact on infectious disease testing as a whole?”
Publication date: June 15, 2022
Page count: 574
COVID-19 Drives a surge in demand but what is the long term impact? The microbiology lab may disappear while multiplexing takes center stage.
The Infectious Disease Molecular Diagnostics sector of the clinical diagnostics industry is poised for record growth. A market that just keeps on growing but is spiking as an enormous C19Dx demand sweeps over the globe. Find out the numbers and exciting developments in multiplex assays which threaten to change diagnosis and treatment, whilst also limiting the threat of anti microbial drug resistance (AMR).
Infectious disease testing directly benefits from the explosion in biotechnology, particularly genomics. A range of dynamic trends are pushing market growth and company valuations, such as:
- Multiplex testing
- Emerging economies and global prosperity
- Biotechnology advances in genetics
- Pathogen evolution
- Climate change
- Rise of rapid testing
Exciting technical developments, especially in the seesaw between sequencing and immunoassay, hold the promise of a dynamic, growing and evolving world market that holds the promise of diagnostics taking the lead in infectious disease eradication.
The report has 574 pages of detailed information including a complete list of Current 2022 United States Medicare Fee Payment Schedules to help sharpen your pricing.
The report includes detailed breakouts for 15 countries and 4 regions. A detailed breakout for any additional country is available to purchasers of the report.
Our research makes you the expert in your organization. Get our research team working for you by ordering this comprehensive report. Check all your licensing options however your order is available as a credit if you wish to upgrade to more information. We wrote this report and we are ready, by phone or email, to help you use it. As always, assistance and additional specific data is provided without additional charges with the corporate license.
All report data is available in Excel format on request with the cororate license.
Make investment decisions and valuations with confidence using the latest data.
ABOUT THE LEAD AUTHOR
Mr. Greg Powell, B.SC., M.B.A is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell’s education includes:
- B.Sc. (Chemistry) University of BC
- M.B.A. (Finance and Policy) University of BC
- Market Research Seminar - Burke Institute
- Finance for Senior Executives - Harvard Business School